Aurinia Pharm Ord (AUPH) Stock Price, Quote & News

Company Profile

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement wit...

Industry: Biotechnology

Sector: Healthcare

Phone: 250 744 2487

Fax: 250 708 4345

Website: www.auriniapharma.com

Address:

#140, 14315 – 118 Avenue, Edmonton, Canada

Martinsucks Feb. 4 at 1:50 AM

$AUPH so these bums only update us 4 times a year? Why don't the hedge fund people ask questions during the earnings call? Like why are there never updates about trials or patent news. This is one oddly ran company. This is

1 · Reply

IDrinkandKnowThings Feb. 4 at 12:34 AM

$AUPH Why does the CMO have so few shares? Only 120k?

1 · Reply

Auphiliate Feb. 3 at 11:46 PM

$AUPH Thank you for the clarification! 😊

0 · Reply

RicardoDelJuego Feb. 3 at 11:06 PM

$AUPH In case anyone's curious, it's an SEC filing for a small market sell by the CMO for tax purposes: https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319745634&type=PDF&symbol=AUPH&cdn=4b3af026a1addf780aba233135b654ea&companyName=Aurinia+Pharmaceuticals+Inc&formType=4&formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&dateFiled=2026-02-03

1 · Reply

Auphiliate Feb. 3 at 10:14 PM

$AUPH 🤦‍♀️ Wrong notice!!! 😬

0 · Reply

Dameistro Feb. 3 at 10:07 PM

$AUPH you've got mail!

0 · Reply

BABYHAIR Feb. 3 at 9:49 PM

$AUPH https://auriniacareers.ttcportals.com/jobs/17298350-junior-accountant Could just be a back fill for someone who left, or maybe the senior accountants are busy elsewhere? Junior accountant and quality contractors….clean books and clean data. Interesting.

1 · Reply

biolurker1 Feb. 3 at 8:41 PM

$AUPH How many millions has he made? Wanna bet Peter Greenleaf is feeling good about his tenure here? Imo

0 · Reply

Auphiliate Feb. 3 at 8:12 PM

$AUPH Weird markets today. Glad I bought GD on the dip, it’s one of a few very green in my portfolio today! Told you-know-who guess I’ll be paying for all our dining out this year!!! 😂

0 · Reply

jdoldnumber7 Feb. 3 at 8:04 PM

$AUPH C'mon, get your head out of your ass and let's go!

1 · Reply

Aurinia Pharmaceuticals Inc. (AUPH) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 6:00 AM EST - 3 months ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress

Nov 3, 2025, 7:31 AM EST - 3 months ago

Wall Street Breakfast Podcast: FDA Executive Controversy

Nov 3, 2025, 6:00 AM EST - 3 months ago

Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025

Oct 22, 2025, 11:20 PM EDT - 3 months ago

Aurinia Pharmaceuticals: Lupkynis Growth And AUR200 Pipeline Justify Buy Rating

Oct 15, 2025, 6:00 AM EDT - 3 months ago

Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025

Sep 29, 2025, 8:27 PM EDT - 4 months ago

Aurinia Responds to Now Retracted LinkedIn Post

Aug 6, 2025, 6:02 PM EDT - 6 months ago

Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)

Jul 31, 2025, 5:57 PM EDT - 6 months ago

Aurinia Pharmaceuticals Inc. (AUPH) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 6:00 AM EDT - 6 months ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025

Jul 22, 2025, 6:00 AM EDT - 7 months ago

Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025

Jul 7, 2025, 12:49 PM EDT - 7 months ago

The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity

Jun 30, 2025, 6:00 AM EDT - 7 months ago

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)

Jun 29, 2025, 5:00 PM EDT - 7 months ago

Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025

May 22, 2025, 6:00 AM EDT - 9 months ago

New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis

May 12, 2025, 12:56 PM EDT - 9 months ago

Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance

May 12, 2025, 11:04 AM EDT - 9 months ago

Aurinia Pharmaceuticals Inc. (AUPH) Q1 2025 Earnings Call Transcript

May 12, 2025, 6:00 AM EDT - 9 months ago

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

May 5, 2025, 6:00 AM EDT - 9 months ago

Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025

Apr 30, 2025, 6:00 AM EDT - 9 months ago

Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting

Apr 29, 2025, 6:00 AM EDT - 10 months ago

ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting

Apr 26, 2025, 10:54 AM EDT - 10 months ago

Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth

Apr 23, 2025, 4:05 PM EDT - 10 months ago

Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting

Feb 27, 2025, 2:11 PM EST - 1 year ago

Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations

Feb 27, 2025, 10:32 AM EST - 1 year ago

Aurinia Pharmaceuticals Inc. (AUPH) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 6:00 AM EST - 1 year ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

Feb 21, 2025, 4:09 PM EST - 1 year ago

Aurinia Pharmaceuticals: There's Still Time For Sales Growth

Feb 20, 2025, 4:05 PM EST - 1 year ago

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

Jan 22, 2025, 12:29 PM EST - 1 year ago

3 Biotech Stocks With Notable Insider Buying

AZN COGT JAZZ ONC XBI ZYME

Nov 18, 2024, 5:53 PM EST - 1 year ago

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Nov 15, 2024, 6:00 AM EST - 1 year ago

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Nov 14, 2024, 6:00 AM EST - 1 year ago

Aurinia to Participate in Jefferies London Healthcare Conference

Nov 8, 2024, 12:15 PM EST - 1 year ago

Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon

Nov 7, 2024, 11:44 AM EST - 1 year ago

Aurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 6:10 AM EST - 1 year ago

Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

Nov 7, 2024, 6:00 AM EST - 1 year ago

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

Oct 30, 2024, 4:05 PM EDT - 1 year ago

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024

Oct 11, 2024, 6:00 AM EDT - 1 year ago

Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024

Sep 24, 2024, 8:10 AM EDT - 1 year ago

Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis

Sep 19, 2024, 12:54 PM EDT - 1 year ago

3 Small Biotech Stocks With The 'Big Mo' Right Now

CORT VRDN

Sep 19, 2024, 7:55 AM EDT - 1 year ago

Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment

Sep 18, 2024, 4:41 AM EDT - 1 year ago

Aurinia Pharmaceuticals: This Recovery Can Continue

Sep 13, 2024, 6:00 AM EDT - 1 year ago

Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 12, 2024, 4:05 PM EDT - 1 year ago

Aurinia Announces Board Restructuring

Sep 5, 2024, 6:00 AM EDT - 1 year ago

Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial

Aug 28, 2024, 6:00 AM EDT - 1 year ago

Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board

Aug 1, 2024, 1:52 PM EDT - 1 year ago

Aurinia Pharmaceuticals, Inc. (AUPH) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 6:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results

Jul 19, 2024, 6:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024

Martinsucks Feb. 4 at 1:50 AM

1 · Reply

IDrinkandKnowThings Feb. 4 at 12:34 AM

$AUPH Why does the CMO have so few shares? Only 120k?

1 · Reply

Auphiliate Feb. 3 at 11:46 PM

$AUPH Thank you for the clarification! 😊

0 · Reply

RicardoDelJuego Feb. 3 at 11:06 PM

1 · Reply

Auphiliate Feb. 3 at 10:14 PM

$AUPH 🤦‍♀️ Wrong notice!!! 😬

0 · Reply

Dameistro Feb. 3 at 10:07 PM

$AUPH you've got mail!

0 · Reply

BABYHAIR Feb. 3 at 9:49 PM

1 · Reply

biolurker1 Feb. 3 at 8:41 PM

$AUPH How many millions has he made? Wanna bet Peter Greenleaf is feeling good about his tenure here? Imo

0 · Reply

Auphiliate Feb. 3 at 8:12 PM

$AUPH Weird markets today. Glad I bought GD on the dip, it’s one of a few very green in my portfolio today! Told you-know-who guess I’ll be paying for all our dining out this year!!! 😂

0 · Reply

jdoldnumber7 Feb. 3 at 8:04 PM

$AUPH C'mon, get your head out of your ass and let's go!

1 · Reply

Amber_Turd Feb. 3 at 7:59 PM

$AUPH When 2025 EoY ER release?

0 · Reply

jdoldnumber7 Feb. 3 at 6:38 PM

$AUPH Maybe the so called rotation out of tech will find it's way into biotechs. The sector could certainly use a tailwind!

1 · Reply

michalinho Feb. 3 at 6:34 PM

$AUPH market take a dive... ibb +4$ swing, now 2$ down....🤪

0 · Reply

Send_IT_or_stepaside Feb. 3 at 4:45 PM

$AUPH We have some life in this old PiG again. Break out time!!! All rip no dip let’s go

1 · Reply

jdoldnumber7 Feb. 3 at 4:42 PM

$AUPH Shorts don't want to give up "yet" that 15.50 resistance point. If so, there wheels will come off....

0 · Reply

michalinho Feb. 3 at 4:36 PM

$AUPH this stock and we all together are complete crank!😂🎈 but i love it! SMA50 to watch....

1 · Reply

ATzmansto Feb. 3 at 4:31 PM

$AUPH Nice to see that bounce back from the weak hands selling earlier......we need news...wake up PG...ITS TIME TO DELIVER!!!!

2 · Reply

Auphiliate Feb. 3 at 4:29 PM

$AUPH Also added $AZN to my watchlist! 🤷‍♀️

0 · Reply

jdoldnumber7 Feb. 3 at 4:27 PM

$AUPH New HOD @ 15.44. 😳

1 · Reply

SCCT2FL Feb. 3 at 4:26 PM

$AUPH an someone jus give us $4 billion and we can move on with life?

0 · Reply

Auphiliate Feb. 3 at 4:25 PM

$AUPH Okay, ready to put Auph back on my watchlist!!! This is OUR MONTH!!! 😊 🙏✝️👑🙏✝️👑🙏

0 · Reply

US_Bull Feb. 3 at 4:24 PM

$AUPH Still waiting for the ADAPY (up 50% today) privatization wish it could happen like yesterday waiting to go all in on Auphie girl. Hope they don't sell her cheap this will be a 50$+ stock after AUR200 gets approved and with corona virus IP. Just simple math and valuation.

3 · Reply

Market Cap	1.92B
Revenue (ttm)	235.13M
Net Income (ttm)	5.75M
EPS (ttm)	N/A
PE Ratio	22.89
Forward PE	17.29
Profit Margin	2.45%
Debt to Equity Ratio	0.00

Volume	897,400
Avg Vol	1,183,104
Day's Range	N/A - N/A
Shares Out	131.84M
Stochastic %K	77%
Beta	1.46
Analysts	Sell
Price Target	$16.71